Hence, our preliminary results suggest that some adult patients with r/r Burkitt lymphoma can benefit from novel treatment strategies involving CD19/CD22 CAR T cell immunotherapy or its combination with ASCT. The gene discussed is CD22; the disease is Burkitt lymphoma.